AKP Stock Chart & Stats
€8.35
€0.00(0.00%)
At close: 4:00 PM EST
€8.35
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.90 - €13.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€174.29M
Enterprise Value€180.92
Total Cash (Recent Filing)€41.02M
Total Debt (Recent Filing)€25.74M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Jul 29, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding13,305,624
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.96
Price to Sales (P/S)1.22
P/FCF Ratio31.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.91Price Target Upside78.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.11
Revenue Forecast (FY)€104.08M
Bulls Say, Bears Say
Bulls Say
Gross Margin ExpansionOperational and manufacturing productivity gains that lifted gross margin materially reflect structural improvement. Lean initiatives, higher throughput and equipment investments can permanently lower unit costs and support higher EBITDA conversion if the company sustains volumes across its orthopedic and regenerative portfolio.
Commercial Momentum And Product AdoptionDurable top-line momentum across Commercial and OEM channels plus accelerating Integrity adoption indicates stronger product-market fit and distribution execution. Broad-based revenue growth and surgeon uptake reduce single-product dependency and support medium-term revenue scalability as commercial investments continue.
Stronger Liquidity And Secured Credit CapacityExtended revolving facility and existing cash position provide durable financial flexibility to fund regulatory programs, commercial expansion, CapEx and opportunistic buybacks. A committed revolver to 2031 reduces short-term refinancing risk and preserves optionality for strategic investments or timing mismatches in OEM orders.
Bears Say
Persistent Operating And Net LossesRecurring operating and net losses have eroded equity and produced a negative return on equity (~-7.4%), constraining the firm's ability to self‑fund growth and return capital. Until profitability consistently turns positive, management must balance reinvestment, regulatory spending and shareholder returns under profit pressure.
Inconsistent Cash Generation And Falling FCFVolatile historical cash generation and a steep drop in free cash flow weaken the firm's ability to sustainably finance R&D, regulatory trials and manufacturing scale without resorting to external financing or cutting investments. Inconsistent FCF raises execution risk during multi‑quarter commercialization efforts.
Regulatory Timing Uncertainty For Key ProductsUncertain FDA timing for Hyalofast (and unclear CINGAL NDA timing) creates structural execution risk: delayed approvals compress expected future U.S. revenue streams, prolong investment before payoff, and complicate planning for manufacturing scale, commercial hires and investor expectations over multiple quarters.
Anika Therapeutics News
AKP FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was €6.90 and its highest was €13.80 in the past 12 months.
What is Anika Therapeutics’s market cap?
Anika Therapeutics’s market cap is €174.29M.
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is Jul 29, 2026 which is in 2 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Apr 29, 2026. The company reported €0.237 earnings per share for the quarter, beating the consensus estimate of -€0.061 by €0.299.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 13,305,624 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of €0.237 in its last earnings report, beating expectations of -€0.061. Following the earnings report the stock price went down -3.759%.
Which hedge fund is a major shareholder of Anika Therapeutics?
Currently, no hedge funds are holding shares in DE:AKP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anika Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€14.91 (78.56% Upside)
€14.91 (78.56% Upside)
Blogger Sentiment
Bullish
DE:AKP Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €196.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.89%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
AKP Company Deck
AKP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights meaningful commercial momentum (13% revenue growth), strong operational improvements (gross margin up ~8 percentage points and adjusted EBITDA lift), accelerating adoption of Integrity and international product strength, supported by a clean balance sheet and active share repurchase. Key near-term concerns include higher operating expenses (notably a onetime $4.9M severance), regulatory timelines for Hyalofast and CINGAL that remain uncertain, OEM channel timing and mix variability, and caution that Q1 margin levels may not be fully sustained quarter-to-quarter. Overall, the positives around revenue growth, margin improvement, pipeline progress and liquidity outweigh the manageable near-term risks and uncertainties.View all DE:AKP earnings summariesAKP Stock 12 Month Forecast
Average Price Target
€14.91
▲(78.56% Upside)